两叉支架用Zotarolimus-Eluting支架进行支架后的三年结果:来自RESOLUTE ONYX后期批准研究的最终结果
Matthew J Price1, Loukas Boutis2, Ajay J Kirtane3
1Scripps Clinic, La Jolla, California.
概括
通过临时支架治疗的Resolute Onyx zotarolimus-eluting支架 (ZES) 在挑战性冠状动脉分支病变方面表现出有利的3年结果. 这项研究支持其在这个患者群体中的安全性和有效性.
科学领域:
- 干预心脏病学 干预心脏病学
- 医疗器械技术 医疗器械技术
- 临床研究 临床研究
背景情况:
- 冠状动脉分叉为皮肤冠状动脉干预带来了复杂的挑战.
- 坚决的Onyx zotarolimus-eluting支架 (ZES) 是一种用于治疗这些病变的设备.
研究的目的:
- 评估Resolute Onyx ZES在使用临时支架技术治疗单个分叉病变的患者中的1年和3年的临床结果.
主要方法:
- 一项前性多中心研究招募了205名因分叉病变而接受皮肤冠状动脉干预的患者.
- 患者接受了使用Resolute Onyx ZES计划中的临时支架治疗.
- 主要终点是1年后目标血管衰竭 (TVF),随访延长至3年.
主要成果:
- 一年的TVF率为7.4%,低于绩效目标.
- 3年后,TVF发生在12.1%的患者中,目标损伤重血管化率为6.0%.
- 没有观察到与目标病变相关的支架血栓形成.
结论:
- 使用临时支架方法使用Resolute Onyx ZES治疗分叉病变,在长达3年的时间内获得了良好的临床结果.
- 这些发现支持Resolute Onyx ZES在适合的分叉病变的长期安全性和有效性.
相关概念视频
Mitral Stenosis III: Medical Management
535
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
535
Acute Coronary Syndrome III: Diagnostic Studies
495
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
495
Atherosclerosis III: Management
741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741


